Core Viewpoint - Annovis Bio, Inc. has successfully closed a registered direct offering, raising approximately $6 million to support its operations in developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's disease [1][2]. Group 1: Offering Details - The company offered 4,000,000 shares of common stock at a price of $1.50 per share [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [2]. - The gross proceeds from the offering were around $6 million, which will be used for working capital and general corporate purposes [2]. Group 2: Regulatory Information - The securities were sold under a "shelf" registration statement on Form S-3, which was filed with the SEC on February 1, 2024, and declared effective on February 12, 2024 [3]. - A prospectus supplement related to the offering was filed with the SEC and is available on their website [3]. Group 3: Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, and focuses on innovative therapies for neurodegenerative diseases [5]. - The company aims to improve patient outcomes and quality of life through its research and development efforts [5].

Group 1 - The event will feature an overview from Dr. Sara Kenkare-Mitra, President and Head of Research and Development, focusing on Alector's multistage pipeline and strategies for addressing neurodegeneration [3] - Alector will highlight its progranulin elevating franchise in frontotemporal dementia with GRN mutations (FTD-GRN) and Alzheimer's disease, specifically discussing the development of latozinemab and nivisnebart (formerly AL101) in collaboration with GSK [3]